Kantonsspital St.Gallen
login

Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11)

Richard Cathomas, Simon J Crabb, Michael Mark, Ralph Winterhalder, Christian Rothermundt, Tony Elliott, Philippe Von Burg, Heike Kenner, Stefanie Hayoz, Simona Berardi Vilei, Daniel Rauch, Enrico Roggero, Markus G Mohaupt, Jürg Bernhard, Gabriela Manetsch, Silke Gillessen Sommer & Swiss Group For Clinical Cancer Research SAKK

abstract

BACKGROUND
We tested whether a switch maintenance treatment with orteronel, an oral inhibitor of androgen biosynthesis, prolongs disease control in men with metastatic castration-resistant prostate cancer (mCRPC) after documented disease stabilization with docetaxel.

METHODS
Men with mCRPC and non-progressive disease after a cumulative dose of ≥300 mg/m2 docetaxel for first line treatment were randomized 1:1 to receive orteronel 300 mg twice daily or placebo. The primary endpoint was event-free survival (EFS) defined as the time from randomization to death or the combination of at least two of radiographic, clinical, or PSA progression. Ninety-six patients per arm were planned to demonstrate an improvement of median EFS from 4 months on placebo to 6.7 months on orteronel (hazard ratio (HR) 0.6; type I error 5% and power 90%).

RESULTS
Forty-seven patients (23 orteronel, 24 placebo) were randomized before premature closure of the trial because of discontinuation of clinical development of orteronel. Median EFS was 8.5 months with orteronel and 2.9 months with placebo (P = 0.001; HR 0.32; 95%CI 0.15-0.65). Median radiographic progression-free survival (rPFS) was 8.5 and 2.8 months (P = 0.02; HR 0.42; 95%CI 0.20-0.91) in the orteronel and placebo arm, respectively. PSA decline ≥50% was seen in 57% on orteronel and 4% on placebo. Toxicity was mainly mild, one patient on orteronel developed transient grade 3 adrenal insufficiency and one grade 4 pneumonitis.

CONCLUSIONS
Orteronel significantly prolongs EFS in men with mCRPC who achieve disease stabilization with docetaxel. The concept of switch maintenance therapy in mCRPC warrants further research. Prostate 76:1519-1527, 2016. © 2016 Wiley Periodicals, Inc.
   
citation Cathomas R, Crabb S J, Mark M, Winterhalder R, Rothermundt C, Elliott T, von Burg P, Kenner H, Hayoz S, Vilei S B, Rauch D, Roggero E, Mohaupt M G, Bernhard J, Manetsch G, Gillessen Sommer S, Swiss Group for Clinical Cancer Research SAKK . Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11). Prostate 2016; 76:1519-1527.
   
type journal paper/review (English)
date of publishing 25-07-2016
journal title Prostate (76/16)
ISSN electronic 1097-0045
pages 1519-1527
PubMed 27457964
DOI 10.1002/pros.23236